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Blood group variants are characteristic of population groups, and can show conspicuous 
geographic patterns. Interest in the global prevalence of the Duffy blood group variants is 
multidisciplinary, but of particular importance to malariologists due to the resistance generally 
conferred by the Duffy-negative phenotype against Plasmodium vivax infection. Here we collate 
an extensive geo-database of surveys, forming the evidence-base for a multi-locus Bayesian 
geostatistical model to generate global frequency maps of the common Duffy alleles to refine 
the global cartography of the common Duffy variants. We show that the most prevalent allele 
globally was FY*A, while across sub-saharan Africa the predominant allele was the silent FY*BES 
variant, commonly reaching fixation across stretches of the continent. The maps presented not 
only represent the first spatially and genetically comprehensive description of variation at this 
locus, but also constitute an advance towards understanding the transmission patterns of the 
neglected P. vivax malaria parasite. 
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First described 60 years ago in a multiply transfused haemo-lytic patient who lent his name to the system1, the Duffy blood group has since been of interest in diverse fields from 
anthropology2 to genetics3 and malariology4,5. Being of only occa-
sional clinical significance6, much of the research into this weakly 
immunogenic blood group has been concerned with establishing 
characteristic expression patterns among populations. Easily diag-
nosable, the Duffy blood group quickly became part of the pack-
age of commonly investigated blood groups used to characterize 
the world’s populations7 and assess relatedness between communi-
ties. Interest in the Duffy blood group rose substantially, however, 
following experimental demonstration of the malaria parasite 
Plasmodium vivax’s dependency on the Duffy antigen for estab-
lishing erythrocytic infection8–10, and therefore that erythrocytes 
lacking the antigen were refractory to this parasitic infection. This 
Duffy negativity phenotype, long known to be common among 
sub-Saharan African populations11, provided an explanation for 
the apparent absence of P. vivax among these populations and their 
diaspora12. To date, no other erythrocyte receptor has been described 
for P. vivax, although some cases of infection have been reported in 
Duffy-negative individuals13–15. Furthermore, the universal expres-
sion of the Duffy antigen binding protein (PvDBP) has made this 
merozoite invasion ligand protein a prime P. vivax vaccine target16. 
The role of the Duffy receptor in P. vivax infection, therefore, allows 
the Duffy-negative phenotype to be a proxy of host resistance to 
blood stage infection17.
Recognizing its physiological function as a chemokine receptor 
involved in inflammation, the Duffy antigen is also known as the 
Duffy antigen receptor for chemokines (DARC). Although specific 
mechanisms underlying its functions remain uncertain, there is 
interest in DARC as an explanatory variable for population-specific 
differences in disease susceptibility18, as demonstrated by ongoing 
research into its role in inflammation-associated pathology and 
malignancy18,19, and the recent, though highly controversial20, surge 
in interest around the antigen’s role in HIV infection21.
The monogenic Duffy system was the first human blood group 
assigned to a specific autosome: position q21–q25 on chromosome 
1 (ref. 22). The gene product has two main variant forms: Fya and Fyb 
antigens, which differ by a single amino acid (Gly42Asp), encoded 
by alleles FY*A and FY*B, which are differentiated by a single base 
substitution (G125A)23,24. Duffy expression is disrupted by a T to C 
substitution in the gene’s promoter region at nucleotide  − 33, pre-
venting transcription and resulting in the null ‘erythrocyte silent’ 
(ES) phenotype. This promoter-region variant is commonly hap-
lotypically associated with the FY*B coding region (corresponding 
to the FY*BES allele)24, although occasional reports of association 
with the FY*A sequence have been published (FY*AES allele)25,26. 
These four alleles combine to ten possible genotypes (Fig. 1), with 
FY*A and FY*B alleles expressed codominantly over the null vari-
ants FY*BES and FY*AES. Genotypes therefore correspond to four 
phenotypes: Fy(a+b+), Fy(a+b−), Fy(a−b+) and Fy(a−b−). Further 
details about the genetics and molecular aspects of the Duffy 
system, including other rare variants such as the weakly expressed 
FY*X allele27 (expressed as the Fy(b + weak) phenotype), are fully 
discussed by Langhi and Bordin23 and Zimmerman24.
The common Duffy alleles present striking patterns of geogra-
phic differentiation, which have only once been mapped spatially, 
as part of Cavalli-Sforza et al.’s28 efforts to unravel the genetic 
Global database of Duffy
blood group frequencies
(1950–2010)
Survey exclusion rules
N by data type
(single data type per site)
N
examined
Phenotype-a
Fy(a+)
Fy(a–)
Phenotype-b
Fy(b+)
Fy(b–)
Promoter
Fy(+)
Fy(–)
Phenotype
Fy(a+b+)
Fy(a+b–)
Fy(a–b+)
Fy(a–b–)
Location
Predicted global distribution of
FY*A allele frequency
Model validation
Predicted global distribution of
FY*BES allele frequency
Global Duffy negativity phenotype
frequency map: Fy(a–b–)
(FY*BES allele frequency)2
Predicted global distribution of
FY*B allele frequency
Bayesian geostatistical model with
Hardy–Weinberg principles
Africa
covariate
FY*A/*A
FY*A/*B
FY*B/*B
FY*A/*AES
FY*A/*BES
FY*B/*AES
FY*B/*BES
FY*AES/*AES
FY*AES/*BES
FY*BES/*BES
Genotype
Figure 1 | Schematic overview of the procedures and methods. Blue diamonds describe input data. White boxes within the ‘N by data type’ diamond 
represent different possible data types, with each spatially unique survey being represented by only one white box. orange boxes denote models and 
experimental procedures. Green rods indicate model outputs.
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history of human populations. Alleles were mapped in isolation of 
each other (FY*A, FY*B and FY*BES) using limited subsets of data 
which directly informed the frequency of each particular variant. 
Previous methodology, which used a sequential inverse distance 
weighting algorithm, was unable to estimate uncertainty in the 
mapped predictions. Since this publication in 1994, new data have 
been generated, much of which have benefitted from full genotyp-
ing. In addition, significant advances have been made to geostatisti-
cal mapping techniques allowing more rigorous predictions of spa-
tially continuous variables using data obtained at a limited number 
of spatial locations29, and varied data inputs to inform all output 
predictions simultaneously.
Here we first assembled an updated data set based on a 
thorough review of published and unpublished data, then used 
this to generate global maps of the Duffy alleles and the Duffy nega-
tivity phenotype using a bespoke Bayesian geostatistical model. 
This generated for every location on a gridded surface a posterior 
distribution of all predicted values from the model’s thousands 
of iterations, representing a complete model of uncertainty from 
which median values were derived to generate point-estimate maps. 
In addition to providing fundamental biomedical descriptions 
of human populations with potential applications for explaining 
population-level variation to a range of clinical conditions19, these 
maps are intended to support contemporary analyses of P. vivax 
transmission risk17.
Results
The survey database. Literature searches identified 821 spatially 
unique data points of Duffy blood type prevalence matching the 
database inclusion criteria for representativeness (Supplementary 
Data). These represented a total of 131,187 individuals sampled, 
17.8% of whom were surveyed on the African continent (Table 1). 
Of this total, 536 surveys were geopositioned as points (≤25 km2), 
and 285 mapped as polygon centroids. Polygons were digitized 
and centroid coordinates calculated in GIS software (ArcView 
GIS 3.2 and ArcMap 9.3, ESRI). Surveys reported only to province 
or country level were considered to lack sufficient geographical 
specificity and were thus excluded. A total of 89 additional data 
points were excluded, as they could not be located with sufficient 
precision. The selected data points were relatively evenly distributed 
between regions, with 32% in the Americas, 25% in Africa, 26% in 
Asia and 17% in Europe (Fig. 2). Survey sample sizes were highly 
variable: ranging from 1 to 2,470. The mean size was 160 and the 
median 99.
Serological techniques were the only methods used for blood 
typing until the 1990s, (Supplementary Fig. S1). Half of the surveys 
(49%) used anti-Fya antiserum only, thus were recorded as ‘Pheno-
type-a’ data types (402 of 821 surveys). Complete ‘Phenotype’ data 
were provided in 247 surveys (30%). Molecularly diagnosed ‘Geno-
type’ and ‘Promoter’ data (9 and 12%, respectively) were only com-
monly reported in post-2000 surveys, and mainly across Africa (71% 
of the 168 DNA-based records were from Africa). The five categories 
of data types are summarized in Table 2, and the spatial distribution 
of each is represented by the colour-coded data point map in Figure 
2. Relative proportions of each variant-type reported by data type and 
continent are displayed in Table 1; further summaries of the data are 
presented graphically by decade in Supplementary Figures S1–S2.
The maps. To generate continuous global maps from the assembled 
database, a Duffy-specific geostatistical model was developed (Supple-
mentary Methods). Its key features are as follows: first, to incorpo-
rate all genotypic variants and data types simultaneously; second, 
to predict any genotype or phenotype frequency desired; third, to 
allow for local heterogeneity; and fourth, to take into account sam-
pling error through sample size, while also generating uncertainty 
estimates with the prediction at each spatial unit (pixel).
Allele frequencies. Continuous global frequency maps of each 
of the three common Duffy alleles (FY*A, FY*B and FY*BES) were 
generated simultaneously, along with summaries of uncertainty in the 
predictions quantified by the 50% interquartile range (IQR; Fig. 3). 
Full statistical summaries of the model parameters at each locus are 
provided in Supplementary Table S1. The silent FY*AES allele could 
not be modelled spatially due to its rarity (see Methods).
The allele frequency maps reveal strong geographic patterns, the 
most conspicuously focal being the distribution of the silent FY*BES 
allele across sub-Saharan Africa. Allelic frequencies across 30 coun-
tries in this region are characterized by  > 90% FY*BES and frequen-
cies of 0–5% for FY*A and FY*B (Fig. 3a–c). Frequencies indicate 
fixation (that is, frequencies of 100% (ref. 30)) in parts of west, 
central and east Africa, suggesting total refractoriness of the local 
population to P. vivax infection3,30. The FY*BES allele, however, is not 
confined to the mainland African sub-continent, with frequencies 
predicted above 80% across Madagascar and above 50% through 
the Arabian Peninsula (Fig. 3c). Low allelic frequencies have also 
spread into the Americas, notably along the Atlantic coast and in the 
Caribbean. Median frequencies of 5–20% are predicted across India 
and up to 11% in South-East Asia.
Allelic heterogeneity is greatest in the Americas, with all three 
alleles predicted as being present and with only localized patches 
of predominance of single alleles. The FY*A allele (Fig. 3a) is close 
to fixation across pockets of eastern Asia, and remains high with 
Table 1 | Summary of input data.
Total individuals 
sampled Africa Americas Asia Europe World
23,349 37,410 32,971 37,457 131,187
17.8% 28.5% 25.1% 28.6%
Genotype 1,720 1,107 5,993 336 9,156
 FY*A/*A 40 183 5,805 42 6,070
 FY*A/*B 88 341 24 174 627
 FY*B/*B 49 217 6 117 389
 FY*A/*AES 0 0 157 0 157
 FY*A/*BES 226 122 0 0 348
 FY*B/*AES 0 0 0 0 0
 FY*B/*BES 190 122 1 1 314
 FY*AES/*AES 0 0 0 0 0
 FY*AES/*BES 4 0 0 0 4
 FY*BES/*BES 1,123 122 0 2 1,247
Phenotype 11,370 10,939 11,143 17,126 50,578
 Fy(a+b+) 1,448 3,841 2,471 7,355 15,115
 Fy(a+b−) 1,338 3,904 6,821 4,872 16,935
 Fy(a−b+) 2,493 2,595 1,493 4,873 11,454
 Fy(a−b−) 6,091 599 358 26 7,074
Promoter 7,290 803 187 104 8,384
 Fy(+) 7,266 406 0 0 7,672
 Fy(−) 24 397 187 104 712
Phenotype-a 2,821 24,420 15,648 17,891 60,780
 Fy(a+) 589 19,950 12,436 11,616 44,591
 Fy(a−) 2,232 4,470 3,212 6,275 16,189
Phenotype-b 148 141 0 2,000 2,289
 Fy(b+) 1 55 0 1,651 1,707
 Fy(b−) 147 86 0 349 582
Total sites 203 265 217 136 821
surveyed 24.7% 32.3% 26.4% 16.6%
The table shows the total number of individuals sampled by continent, broken down by variant 
within each data type category. Totals are shown in bold. The number of spatially unique sites 
in each continent is given in the bottom row.
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median frequencies above 80% predicted across large extents of 
south Asia, Australia and in populations from Mongolia and east-
ern parts of China and Russia. The allele is also at high frequencies 
( > 90%) in Alaska and northwest Canada. Outside these regions of 
highest predominance, FY*A remains relatively common outside 
the African continent, with median frequencies  > 50% predicted 
across 67.7% of the global surface. The FY*B allele (Fig. 3b) is the 
allele least prevalent globally, with a maximum predicted median 
frequency of 83% (thus fixation is never reached). Reflecting 
its reduced prevalence, the distribution of FY*B matches areas of 
highest allelic heterogeneity, where its presence increases to fre-
quencies similar to, or greater than, FY*A and FY*BES. Frequencies 
above 50% are restricted to Europe and pockets of the Americas, 
notably along the east coast of the United States of America. FY*B 
frequencies decrease from their European epicentre eastwards, as the 
FY*A allele becomes predominant in Asia. FY*B is also prevalent in 
the buffer zones around the region of FY*BES predominance, in 
northern, north-eastern and southern Africa.
Duffy negativity phenotype. The phenotype map of Duffy nega-
tivity (Fig. 4) reveals very low frequencies of the homozygous null 
genotype (FY*BES/*BES) from much of the predicted non-African 
FY*BES distribution (Fig. 3c). Despite being present, the low allelic 
frequencies mean that homozygotic inheritance is too low to feature 
in the phenotype map. Therefore, even more pronounced than the 
allele’s distribution, the Duffy negativity phenotype is highly con-
strained to sub-Saharan African populations, and localized patches 
in the Americas. Across the African continent, the phenotype’s 
median frequency is greatest (98–100%) in western, central and 
south-eastern regions from The Gambia to Mozambique, buffered 
by a high median frequency region of ≥90% frequency covering 22 
countries (Fig. 4a). Around this high frequency region, steep clines 
into the Sahel in the north, and Namibia and South Africa in the 
south lead to median phenotypic frequencies of  < 10% in parts of 
these extremities.
Frequencies of Duffy negativity increase by ~10% south of 
the sub-Saharan desert boundary, as defined in the model by the 
Data point
Genotype (n=73) Phenotype-a (n=402)
Phenotype-b (n=4)
Sub-Saharan Africa boundary
Phenotype (n=247)
Promoter (n=95)
Figure 2 | Spatial distribution of the input data points categorized by data type. symbol colours represent the type of information in the survey: orange 
when full genotypes were detected (Genotype); red for full phenotype diagnosis (Phenotype); yellow for expression/non-expression of Duffy antigen 
(Promoter); green and blue for partial phenotypic data, about expression of Fya (Phenotype-a) and Fyb (Phenotype-b) respectively. Total data points  
are n = 821; totals by data type are listed in the legend. The sub-saharan Africa covariate boundary is shown in black.
Table 2 | Diagnostic methods and corresponding classification data type categories.
Diagnostic 
method
Diagnostic 
type
Data type Description Information given Homo/heterozygote 
status
serological Phenotype Phenotype study tested for Fya and 
Fyb
Four phenotypes no
Phenotype-a study only tested for Fya Two data types (Fya+/−): cannot distinguish 
Fy(a−b+) from Fy(a−b−)
no
Phenotype- b study only tested for Fyb Two data types (Fyb+/−): cannot distinguish 
Fy(a+b−) from Fy(a−b−)
no
DnA-based Genotype Promoter study only looked at 
promoter region snP
Distinguishes expression from non-expression:  
cannot distinguish FY*A from FY*B coding region
Yes (promoter snP 
only)
Genotype study looked at promoter 
and a/b snP
Fully distinguishes all individual alleles Yes
snP, single-nucleotide polymorphism.
During the abstraction process, data points were classified into data types according to the diagnostic methodology used.
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GlobCover bare ground data set31 (Fig. 5). This trend of increased 
frequencies is reflected by the positive values associated with the 
sub-Saharan Africa covariate, fully described in Supplementary 
Table S2. The increase is sharpest where there are few underlying 
data points, contrasting with the prediction in data-rich regions, 
such as West Africa, which is smoother across the desert boundary 
due to the abundance of input data overriding its influence.
Prediction uncertainty. The output generated by the Bayesian frame-
work is a predictive posterior distribution for each modelled vari-
able for each 10×10 km pixel on the global grid (and 5×5 km across 
Africa). The posterior quantifies the probabilities associated with 
every candidate value of each modelled variable and therefore rep-
resents a complete description of uncertainty in the model output32. 
The outputs, summarized in Figures 3a–c and 4a, are the median 
values of these distributions. The uncertainties around these 
predictions, represented by the intervals between the 25 and 75% 
quartiles of the posterior distributions (or IQRs), are shown for the 
allele maps in Figures 3d–f and for Duffy negativity in Figure 4b. 
Remarkable certainty in the prediction for high Duffy negativity 
in sub-Saharan Africa is reflected by IQRs of 0–5% for all outputs. 
The absence of data points from the Democratic Republic of the 
Congo leads to a slightly elevated level of uncertainty relative to the 
surrounding region (Figs 4b and 5). Certainty in the prediction of the 
highest frequencies of Duffy negativity is illustrated by the hatched 
areas of ≥95% Duffy negativity prevalence, determined with 75 and 
95% confidence (Fig. 5). As would be expected from the heterogene-
ity in allelic make-up (Fig. 3a,b), the greatest uncertainty in the global 
predictions of FY*A and FY*B prevalence is associated with the pre-
dictions across Europe, western Asia and the Americas (Fig. 3d,e).
Validation statistics. Bespoke validation procedures were deve-
loped to quantify the model’s ability to predict frequencies of each 
allele, as well as the validity in the underlying assumption of Hardy– 
Weinberg equilibrium: first, by validating the Duffy-negative pheno-
type surface; second, by assessing rates of heterozygosity between 
FY*A and FY*B. The model’s predictive ability was quantified by 
assessing the disparity between model predictions and held-out 
subsets of data excluded for validation analyses33. The validations 
were summarized using simple statistical measures: mean error 
(assesses overall model bias) and mean absolute error (quantifies 
overall prediction accuracy as the average magnitude of the errors, 
Supplementary Methods).
First, the mean error in the prediction of the Duffy negativity 
phenotype revealed a slight positive bias in the posterior predic-
tive distribution of Duffy negativity (mean error: 1.3%), while the 
mean absolute error revealed relatively high typical precision in the 
predictions (mean absolute error: 5.8%). Second, the heterozygosity 
validation process identified an overall positive bias in the poste-
rior predictive distribution of rates of heterozygosity (frequencies of 
the FY*A/*B genotype) with mean error of 5.5% and mean absolute 
error of 7.8%. Overall, therefore, the model’s predictive ability for 
the clinically significant Duffy-negative phenotype was relatively 
high, although the assumption of Hardy–Weinberg equilibrium 
was not strongly supported, indicating that better predictions might 
be achieved in future iterations by modelling the fixation index as 
a third geostatistical random field. However, the resulting model 
would be substantially more complicated than the current one, 
which is already a major advance beyond the state of the art, and 
commensurately more difficult to fit. Given the relatively small size 
of the heterozygote deficiency in the holdout data set, we decided 
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Figure 3 | Global Duffy blood group allele frequencies and uncertainty maps. (a–c) Correspond to FY*A, FY*B and FY*BES allele frequency maps, 
respectively (median values of the prediction posterior distributions); (d–f) show the respective interquartile ranges (IQR) of each allele frequency  
map (25–75% interval). Predictions are made on a 5×5 km grid in Africa and 10×10 km grid elsewhere. supplementary Figure s5 is a greyscale image  
of this figure.
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against elaborating the model in the current study. More validation 
results are given in Supplementary Figure S3.
Discussion
The spatial distribution of the Duffy blood group variants has been 
of interest since its discovery 60 years ago because of its link to 
the pathology of both infectious and non-communicable diseases, 
including most notably with P. vivax infection. We have assembled 
an up-to-date database of Duffy phenotypic and genotypic data, 
from which we identified 821 geographically unique community 
surveys, and developed a geostatistical model to generate global 
frequency maps for the main Duffy alleles, as well as the first map 
of the Duffy-negative phenotype. These refined maps and associ-
ated uncertainty measures allow both an assessment of the quality 
and distribution of existing data as well as a discussion of how the 
maps may help direct further research into the interactions between 
Duffy negativity and P. vivax malaria. A detailed comparison with 
the existing maps from Cavalli-Sforza et al.28 is presented in the Sup-
plementary Discussion and Supplementary Figures S8–S10.
The summary median maps presented reveal relatively smooth 
global-scale patterns of geographic differentiation among popula-
tions. Despite being considered the ancestral allele34, our maps show 
a remarkable restriction in the distribution and frequency of the 
FY*B allele, with highest prevalence found in Europe and parts of 
the Americas, with further patches of increased prevalence in areas 
buffering the region of FY*BES predominance in sub-Saharan Africa. 
Frequencies of FY*A prevalence increase with distance from Africa 
and Europe, becoming dominant across south-east Asia, including 
those areas where P. vivax endemicity is highest17. Although the 
FY*BES allele map predicts presence outside the African continent 
and the Arabian Peninsula, its frequencies remain too low for the 
Duffy-negative phenotype frequencies to exceed 10%. Although 
these static contemporary representations of allelic frequencies can-
not alone be interpreted to advance current speculation regarding 
the causative mechanisms of selection of the high frequencies of the 
FY*BES allele4,5,35,36, the Duffy negativity map does reflect visually the 
historical areas of malaria transmission, as defined by Lysenko’s pre-
control era malaria map37 (Supplementary Fig. S4, recently repub-
lished by Piel et al.38)
A major challenge in this study was synthesizing the results of 
surveys, which used a range of diagnostic methods with potentially 
different reliabilities, particularly between genotyping and pheno-
typing methods. The possible influence of such variability on the 
model input is reviewed in detail in the Supplementary Methods, 
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Figure 4 | Global distribution of the Duffy negativity phenotype. (a) Global prevalence of Fy(a − b − ); (b) associated uncertainty map. uncertainty is 
represented by the interval between the 25 and 75% quartiles of the posterior distribution (IQR). supplementary Figure s6 is a greyscale image of  
this figure.
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but is not considered to have major influence on the final output. 
By categorizing results into five data types (Table 2) and developing 
a versatile geostatistical model, we were able to draw information 
from the differing data types in our full data set to generate each 
allele frequency map simultaneously. The Genotype data, gener-
ated from molecular diagnostic methods only widely available after 
the previous maps28 were published, were most informative for the 
model. Despite a generally good global spread of survey data points 
(Fig. 2), the uncertainty maps allow identification of areas where 
additional data would have proportionally greatest impact on our 
understanding of the distributions. Both the quality (data type) 
and quantity (data distribution) of the data affect the uncertainty 
measures. Uncertainty is increased by both scarcity of input data 
(exemplified across the Arabian Peninsula where only Phenotype-a 
data were available) and heterogeneity (characteristic of the Ameri-
cas where populations of diverse origins coexist; Figs 3d–f and 5). 
In contrast, areas of lowest uncertainty match data-rich regions and 
areas of near-fixation, illustrated by the hatched areas of 95% confi-
dence in the prediction shown in Figure 5. Scarcity of input data also 
leaves us uncertain about possible fine-scale variation of allelic het-
erogeneity. This is demonstrated by the relatively high uncertainty 
in the predictions of the patchily distributed FY*BES allele across the 
Americas, where spatial heterogeneity is expected to be high and 
perhaps not fully represented by the data set. As well as improv-
ing reliability in the current predictions, additional molecularly 
diagnosed data would allow refinements of the model to include 
additional polymorphic variants, such as the low-frequency weak 
FY*X variant39. This is discussed in detail in the Supplementary 
Discussion.
Reflecting the growing appreciation of P. vivax’s public health sig-
nificance and the realization that it is not ‘benign’16,40,41, the parasite’s 
relationship with the Duffy receptor is the primary focus of contem-
porary studies of the Duffy antigen. However, two lines of evidence, 
both from a community and an individual standpoint, support the 
need for further research into the Duffy–parasite association. First, 
contrary to expectation, there is evidence of P. vivax transmission in 
areas mapped with highest Duffy negativity frequencies. Although 
widespread surveys have failed to identify the parasite in this region 
(including a continental-wide survey by Culleton et al.42, and the data 
set of community parasite rate surveys displayed in Fig. 5), reports of 
infected mosquitoes13, travellers17 and exposed individuals43 suggest 
low level transmission. Across this predominantly Duffy-nega-
tive region, very low numbers of Duffy-positive individuals were 
identified (0.6% of individuals in 123 surveys across the 98–100% 
Fy(a−b−) region; Supplementary Table S3). To see whether these 
two observations can be reconciled to explain transmission, math-
ematical modelling is needed to estimate the basic reproductive 
number (R0) of P. vivax (as done for Plasmodium falciparum44) to 
Figure 5 | Characteristics of the Duffy negativity phenotype in Africa. This figure shows the covariate line (in green), which separates sub-saharan 
African populations from the rest of the continent; hatched areas indicate areas of confidence in the distribution of ≥95% Duffy negativity frequency: 
with 75%and 95% confidence. Black data points correspond to the input Duffy data points (n = 821). Yellow stars indicate locations of P. vivax-positive 
community surveys (n = 354), and blue stars P. vivax-negative surveys (n = 1405) (data assembled by the malaria Atlas Project17,46). supplementary  
Figure s7 is a greyscale image of this figure.
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help assess whether the very low predicted frequencies of suscepti-
ble Duffy-positive hosts could sustain transmission in populations 
mapped as predominantly Duffy negative.
Second, from areas mapped with high Duffy phenotypic hetero-
geneity, P. vivax infections have been identified in Duffy-negative 
hosts (in Madagascar15 and Brazil14). If this phenomenon of infected 
Fy(a−b−) individuals is associated with local Duffy heterogene-
ity, as hypothesized by Ménard et al.15, the Duffy maps presented 
here could be used to target further studies in other heterogene-
ous P. vivax endemic areas17, including southern Africa, Ethiopia, 
southern Sudan and pockets of the Brazilian and Colombian coasts. 
Investigation of P. vivax transmission in these areas particularly, 
but also across regions with a spectrum of characteristic Duffy 
phenotypes, could provide vital public health insights into P. vivax 
populations at risk, particularly when coupled with host-level data 
on Duffy types.
In this era of increasing concern about the P. vivax parasite, 
we believe that a contemporary spatial description of the preva-
lence of the Duffy antigen receptor is essential for optimizing our 
understanding of the parasite’s clinical burden. The geopositioned 
database and maps represent a new effort to document the spatial 
characteristics of a fundamental biomedical trait implicated in hae-
matological and other clinical contexts. The versatile geostatistical 
model developed was adapted to a multiple-locus trait, informed 
by a range of input data types to generate a suite of output products. 
Such methods are uncommonly used by the genetics community, 
but we believe could have an important role in the current era of 
large-scale spatial genomic analyses. Although we present a carto-
graphic suite which we believe constitutes a significant improve-
ment from previously published attempts28 (see Supplementary 
Discussion and Supplementary Figs S8–S10), this study highlights 
limitations to our current knowledge of the Duffy blood group: both 
in terms of the scarcity of data from many areas, and in relation to 
the P. vivax invasion pathway. All collated data and model code will 
be made openly accessible.
Methods
Analysis outline. The methodological steps of this work were threefold: first, to 
assemble a library of full-text references describing Duffy blood group surveys, 
complemented with unpublished data; second, to abstract the Duffy frequency 
data from each source and to georeference survey locations; and third, to develop 
a spatial model which uses the full heterogeneous data set assembled to predict 
continuous global frequency maps of the Duffy variants. A schematic overview 
of the methodological process is given in Figure 1, and each component is now 
discussed in more detail.
Library assembly. Systematic searches, adapted from those developed by the 
Malaria Atlas Project (MAP, http://www.map.ox.ac.uk)45,46, were conducted in an 
attempt to assemble a comprehensive database of Duffy blood group surveys dat-
ing from 1950, the publication year of Cutbush’s description of the blood group1. 
Keyword searches for ‘Duffy’ and ‘DARC’ were conducted in online bibliographic 
archives PubMed (http://www.pubmed.gov), ISI Web of Knowledge (http://isi-
webofknowledge.com) and Scopus (http://www.scopus.com). Searches were last 
performed on 08 December 2009. Manual duplicate removal and abstract reviews 
of the amalgamated search results identified 303 references likely to contain data, 
in addition to the 296 and 60 references from existing databases published by 
Mourant et al.47 and Cavalli-Sforza et al.28, respectively. Full-text searches were then 
conducted for each of these 659 unique references. Following direct contact with 
researchers, 15 additional unpublished data sets were also included. All sources 
from which data met the criteria for inclusion are cited in the Supplementary 
References.
Data abstraction and inclusion criteria. The library of assembled references was 
reviewed to identify location-specific records of Duffy variant frequencies repre-
sentative of local populations. Data were abstracted into a customized database, 
including population descriptions and ethnicities as reported by authors, methodo-
logical details and Duffy variant frequencies. Potentially biased samples of hospital 
patients with malaria symptoms or recently transfused individuals were excluded, 
as were family-based investigations and studies focussing on selected subgroups 
of larger mixed communities (for example, African-American communities in 
American cities). No constraints were placed on sample size, as the geostatistical 
framework downweighted the information content of very small surveys in accord-
ance with a binomial sampling model33.
Geopositioning. The geographic location of each survey was determined as pre-
cisely as possible using the georeferencing protocol previously described by Guerra 
et al.45. Author descriptions of survey sites were used to verify locations identified 
in digital databases including Microsoft Encarta (Microsoft Corporation), and 
online databases such as Geonames (National Geospatial-Intelligence Agency, 
http://geonames.nga.mil/ggmagaz/, accessed June–December 2009) and Global 
Gazetteer Version 2.2 (Falling Rain Genomics, http://www.fallingrain.com/world/
index.html, accessed June–December 2009). Surveys were categorized according to 
the area they represented: points (≤25 km2), and small (≥25 and ≤100 km2) or large 
polygons (>100 km2).
Duffy blood group data. In addition to prevalence data of specific variants, details 
of diagnostic methodology were recorded to classify the type of information 
provided from the survey (Table 2). According to the range of possible serologi-
cal and molecular diagnostic methods, data points were classified into five data 
types: ‘Genotype’, where full genotypes were reported; ‘Phenotype’, if full serological 
diagnoses were performed (with both anti-Fya and anti-Fyb antisera); ‘Promoter’, 
if results reported only antigen expression/non-expression without distinguish-
ing Fya from Fyb (data were mainly from molecular studies examining only the 
promoter-region locus, but also occasionally from serological tests not distinguish-
ing between antigenic variants); ‘Phenotype-a’, if only the Fya antigen was tested 
for (meaning that presence of Fyb antigen could not be distinguished from the 
negativity phenotype); and ‘Phenotype-b’, if the study was only concerned with Fyb 
expression (Fig. 6).
Modelling. To accommodate the five input data types described and to model the 
multiallelic system, the two primary loci differentiating the Duffy variants were 
considered simultaneously. These were position  − 33 in the promoter region, which 
determines expression/non-expression, and base position 125 of exon 2, differen-
Phenotype-a
Fya/b coding locus
Geostatistical model framed by Hardy–Weinberg principles
Promoter locus
T-33C variantG125A variant
Phenotype-b Promoter Phenotype Genotype
Predicted FY*A
allele frequency
Predicted FY*B
allele frequency
Predicted FY*BES
allele frequency
Predicted FY*AES
allele frequency
Figure 6 | Relationship between data types and the information conveyed to the model. Left to right along the large arrow, the deepening colour intensity 
represents each data type’s relative influence on the model output. Dashed vertical arrows denote information about only one locus. Thickness of vertical 
lines emphasizes the completeness of the data type. orange boxes represent the Bayesian model. Green rods indicate output data. The grey horizontal 
arrow and greyed FY*AES prediction rod indicates that this allele was accounted for in the model structure, but not one of the final outputs.
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tiating Fya from Fyb coding regions23. Including the full data set while modelling 
each variant optimizes the model predictions, as each data type informs, either 
directly or indirectly, the frequency of variants at both loci, by ruling out certain 
genotypes. This feature was not possible with previously used mapping models28.
Genetic loci modelled. The genetic loci were considered as two spatially  
independent random fields, but modelled in association: first, the random field 
representing the coding region variant modelled the frequency of Fya or Fyb expres-
sion; and second, a random field represented the probability of the promoter ‘ES’ 
variant being associated with the Fyb coding variant, thus determining prevalence 
of FY*B versus FY*BES alleles. Reports in the data set of the ‘ES’ variant in associa-
tion with the Fya variant (that is, the FY*AES allele) were too infrequent and, when 
identified, were too rare to be modelled as a spatial random field. Therefore, this 
variant was modelled by a small constant. Further details about the model are given 
in the Supplementary Methods.
Sub-Saharan Africa covariate. Preliminary examination of the ‘Genotype’ data set 
confirmed the assumption that the haplotypic association between the Fyb coding 
variant and the ‘ES’ promoter variant, together corresponding to the FY*BES allele, 
was very high within sub-Saharan African populations, but rare outside the region. 
To allow the model to reflect this high probability of association across sub-Saha-
ran Africa, we used a generalized version of the GlobCover Land Cover V2.2 bare 
ground surface (channel 200)31 to differentiate the sub-Saharan populations (pres-
ence), including those living in Madagascar and on other nearby islands (decision 
informed by the ‘Genotype’ data), from the other populations (absence; Fig. 2). This 
binary descriptor was the only covariate used in the model.
Model implementation. The analyses were implemented in a Bayesian model-
based geostatistical framework29, the principal aspects of which have been 
previously described33,48. In brief, the geostatistical model uses Gaussian random 
fields to represent the spatial heterogeneity observed in the data and to predict 
values at unsampled locations. Repeated sampling of the random fields ensures 
that a representative sample of all the possibilities consistent with the input data 
set is used in predicting pixel values at sites where there is no data (Supplementary 
Methods). Estimates for pixels distant from any input data points or in areas of 
high spatial heterogeneity are inherently more difficult to predict precisely, and so 
are associated with greater prediction uncertainty. The posterior median values and 
associated uncertainty (IQR (25th to 75th percent quartile ranges) of the posterior 
distribution) are used to summarize the model’s predictions for each pixel33,49.
Generating the map surfaces. The model’s predictions for allele frequencies 
were mapped at all pixels on the global grid (at 5×5 km in Africa and 10×10 km 
elsewhere). Median values of the posterior distribution were chosen for the maps 
as these were considered more appropriate than mean values, due to the long-tailed 
distributions of the predictions that could strongly skew mean estimates. From 
these allele frequency surfaces, genotype frequencies could be obtained using the 
standard Hardy–Weinberg formula50,51. Thus, the Duffy negativity phenotype was 
expressed by the squared frequency of the silent FY*BES allele (the FY*AES allele 
being too rare to occur in homozygous form).
Model validation. To validate the three allele frequency surfaces and cross-exam-
ine the model’s assumption of Hardy–Weinberg equilibrium, both the frequency of 
Duffy negativity and frequency of FY*A/*B heterozygosity were validated. For each 
validation procedure, the model was run with a random subset of the data set left 
out and predictions at these locations were compared with the observed frequen-
cies. Estimates of the model’s overall bias and precision were quantified as mean 
error and mean absolute error values, respectively (Supplementary Methods).
Availability of data. The survey database and maps are publicly accessible through 
the MAP website (http://www.map.ox.ac.uk) in line with the MAP’s open-access 
policy and the terms of the Wellcome Trust Biomedical Resources Grant (#085406) 
funding this work. 
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